Zhende Medical Future Growth
Future criteria checks 0/6
Zhende Medical's revenue and earnings are forecast to decline at 1.8% and 1.7% per annum respectively. EPS is expected to decline by 8.3% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
-1.7%
Earnings growth rate
-8.3%
EPS growth rate
Medical Equipment earnings growth | 21.4% |
Revenue growth rate | -1.8% |
Future return on equity | 8.7% |
Analyst coverage | Low |
Last updated | 08 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 5,630 | 610 | -6 | 1,071 | 1 |
12/31/2024 | 4,740 | 480 | -212 | 789 | 1 |
12/31/2023 | 4,170 | 200 | -67 | 857 | 1 |
12/31/2022 | 6,022 | 675 | N/A | 763 | 1 |
9/30/2022 | 5,426 | 568 | -295 | 605 | N/A |
6/30/2022 | 4,946 | 489 | -222 | 564 | N/A |
3/31/2022 | 4,362 | 454 | -39 | 706 | N/A |
12/31/2021 | 5,092 | 596 | 122 | 818 | N/A |
9/30/2021 | 6,145 | 934 | 88 | 962 | N/A |
6/30/2021 | 9,491 | 1,939 | 158 | 1,183 | N/A |
3/31/2021 | 11,684 | 2,718 | 1,984 | 3,153 | N/A |
12/31/2020 | 10,399 | 2,549 | 2,028 | 3,121 | N/A |
9/30/2020 | 8,699 | 2,160 | 2,009 | 2,773 | N/A |
6/30/2020 | 4,925 | 1,085 | 1,894 | 2,447 | N/A |
3/31/2020 | 2,243 | 212 | 110 | 437 | N/A |
12/31/2019 | 1,868 | 157 | -76 | 198 | N/A |
9/30/2019 | 1,686 | 140 | -43 | 187 | N/A |
6/30/2019 | 1,526 | 138 | -139 | 153 | N/A |
3/31/2019 | 1,483 | 141 | -259 | -8 | N/A |
12/31/2018 | 1,429 | 130 | -206 | 20 | N/A |
9/30/2018 | 1,388 | 135 | -127 | 19 | N/A |
6/30/2018 | 1,360 | 128 | -112 | 12 | N/A |
3/31/2018 | 1,294 | 119 | 3 | 155 | N/A |
12/31/2017 | 1,306 | 122 | 47 | 191 | N/A |
12/31/2016 | 1,035 | 83 | -21 | 139 | N/A |
12/31/2015 | 1,021 | 79 | N/A | 143 | N/A |
12/31/2014 | 987 | 22 | N/A | 84 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603301's earnings are forecast to decline over the next 3 years (-1.7% per year).
Earnings vs Market: 603301's earnings are forecast to decline over the next 3 years (-1.7% per year).
High Growth Earnings: 603301's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 603301's revenue is expected to decline over the next 3 years (-1.8% per year).
High Growth Revenue: 603301's revenue is forecast to decline over the next 3 years (-1.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603301's Return on Equity is forecast to be low in 3 years time (8.7%).